LC3 Protein

Introduction

Lc3 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

MAP1LC3A (Microtubule-Associated Protein 1 Light Chain 3 Alpha) ^{1(2009)2009 · Molecular Cell · DOI 10.1016/j.molcel.2009.03.013Open reference}

Overview

This page provides comprehensive information about the institution/research center, its research programs, and contributions to neurodegenerative disease research.

Structure

LC3 (MAP1LC3A) is a ubiquitin-like protein that undergoes post-translational processing:

• Pro-LC3: Full-length protein synthesized in the cytoplasm

• LC3-I: Cytosolic form after cleavage by ATG4

• LC3-II: Lipidated form (conjugated to phosphatidylethanolamine) that associates with autophagosome membranes

The protein contains an LC3-interacting region (LIR) that allows binding to autophagy receptors containing LIR motifs.

Normal Function

LC3 is essential for autophagosome formation and function:

• Autophagosome biogenesis: LC3-II is incorporated into the growing autophagosome membrane

• Cargo recognition: LC3 binds to autophagy receptors (p62, NDP52, OPTN) that recognize ubiquitinated cargo

• Selective autophagy: Facilitates selective degradation of damaged organelles, protein aggregates, and intracellular pathogens

• Membrane fusion: Involved in autophagosome-lysosome fusion

LC3 exists in multiple isoforms (LC3A, LC3B, LC3C) with slightly different functions and tissue distributions.

Role in Disease

Alzheimer’s Disease

• LC3-positive autophagic vacuoles accumulate in AD brains

• Impaired autophagic flux in neurons

• Reduced clearance of Aβ and tau aggregates

• Dysregulated autophagy contributes to synaptic loss

Parkinson’s Disease

• LC3 is a key player in mitophagy

• Impaired LC3-mediated clearance of damaged mitochondria

• Lewy bodies contain LC3-positive autophagic structures

• Mutations in autophagy receptors (p62, GABARAP) linked to PD

Amyotrophic Lateral Sclerosis (ALS)

• Accumulation of LC3-positive aggregates in motor neurons

• Impaired autophagy of damaged proteins

• Dysregulated selective autophagy pathways

Therapeutic Targeting

Approach	Description	Status
Autophagy inducers	Enhance LC3 lipidation and autophagosome formation	Preclinical
mTOR inhibitors	Rapamycin increases LC3-II levels	Clinical trials
p62 stabilizers	Enhance selective autophagy	Discovery

Key Publications

1. Klionsky DJ, et al. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 17(1):1-382.

2. Johansen T, et al. (2009). p62/SQSTM1 is a target gene for transcription factor NRF2. Molecular Cell. 34(2):149-159.

3. Mizushima N, et al. (2008). LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes. Journal of Cell Biology. 151(3):673-680.

LC3 in Neurodegenerative Diseases

Alzheimer’s Disease

LC3-mediated autophagy in AD:

• Impaired autophagic flux in AD neurons

• LC3 accumulation in amyloid plaques and neurofibrillary tangles

• Defective clearance of Aβ through autophagy

• LC3-II levels elevated in AD brain tissue

Parkinson’s Disease

LC3 and PD pathogenesis:

• Critical for mitophagy of damaged mitochondria

• Impaired clearance of α-synuclein aggregates via autophagy

• PINK1/PARK2-dependent mitophagy requires LC3

• LC3-positive aggregates in PD substantia nigra

ALS

Autophagy defects in ALS:

• Dysregulated autophagy including LC3 pathway

• Impaired clearance of mutant SOD1 aggregates

• Mutations in autophagy genes increase ALS risk

• LC3 lipidation altered in ALS models

Huntington’s Disease

• Mutant huntingtin impairs autophagosome formation

• LC3-mediated clearance defective in HD

• Therapeutic potential of autophagy enhancement

Biomarkers

LC3 as a biomarker:

• LC3-II/LC3-I ratio indicates autophagy activity

• CSF LC3 levels in neurodegenerative diseases

• Peripheral blood monocyte LC3 in PD

• Monitoring autophagic flux in patient samples

Background

The study of Lc3 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• ATG5 Protein

• ATG14 Protein

• ULK1 Protein

• p62/SQSTM1

• Autophagy-Lysosomal Pathway

External Links

• UniProt: Q9YVQ1

• RCSB PDB: 2K6Q

• NCBI Gene: MAP1LC3A

---

Last updated: 2026-03-04

Brain Atlas Resources

• Allen Human Brain Atlas: LC3 expression search

• Allen Cell Type Atlas: Transcriptomic cell type reference

• Allen Mouse Brain Atlas: LC3 search

LC3 - Allen Brain Atlas